Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition (Q36822126)

16 August 2017

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition (English)

1 reference

16 August 2017

14

1 reference

16 August 2017

5

Klaus Busam

0 references

Georgina V. Long

Georgina V Long

12

0 references

Mario E Lacouture

Mario E Lacouture

4

0 references

Grant McArthur

Grant McArthur

13

0 references

Antje Sucker

15

Antje Sucker

1 reference

16 August 2017

16

Dirk Schadendorf

1 reference

16 August 2017

8

Axel Hauschild

1 reference

16 August 2017

11

Reinhard Dummer

1 reference

16 August 2017

Lisa Zimmer

1

1 reference

16 August 2017

Uwe Hillen

2

1 reference

16 August 2017

Elisabeth Livingstone

3

1 reference

16 August 2017

Klaus Busam

5

1 reference

16 August 2017

Richard D Carvajal

6

1 reference

16 August 2017

Friederike Egberts

7

1 reference

16 August 2017

Mohammed Kashani-Sabet

9

1 reference

16 August 2017

Simone M Goldinger

10

1 reference

16 August 2017

language of work or name

English

0 references

publication date

21 May 2012

1 reference

Journal of Clinical Oncology

16 August 2017

1 reference

16 August 2017

30

1 reference

16 August 2017

19

1 reference

16 August 2017

2375-2383

1 reference

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Mutant BRAF melanomas--dependence and resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

BRAF, a target in melanoma: implications for solid tumor drug development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Final version of 2009 AJCC melanoma staging and classification

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Oncogenic Braf induces melanocyte senescence and melanoma in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

High frequency of BRAF mutations in nevi

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

BRAF targeted therapy changes the treatment paradigm in melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: correlation of increased expression with epidermal hyperplasia

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Drug discovery: inhibitors that activate

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646308

Cyclin D1 expression in melanocytic lesions of the skin

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22614973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22614973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2011.41.1660

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

22614973

1 reference